Citations Appearing in 2017

  1. Andersson, B. S.; Thall, P. F.; Valdez, B. C.; Milton, D. R.; Al-Atrash, G.; Chen, J.; Gulbis, A.; Chu, D.; Martinez, C.; Parmar, S. Fludarabine with Pharmacokinetically Guided IV Busulfan Is Superior to Fixed-Dose Delivery in Pretransplant Conditioning of AML/MDS Patients. Bone Marrow Transplant. 2017, 52 (4), 580.
  2. Ayyar, V. S.; DuBois, D. C.; Almon, R. R.; Jusko, W. J. Mechanistic Multi—Tissue Modeling of Glucocorticoid-Induced Leucine Zipper Regulation: Integrating Circadian Gene Expression with Receptor-Mediated Corticosteroid Pharmacodynamics. J. Pharmacol. Exp. Ther. 2017, 363 (1), 45–57.
  3. Bayard, D. S.; Neely, M. Experiment Design for Nonparametric Models Based on Minimizing Bayes Risk: Application to Voriconazole. J. Pharmacokinet. Pharmacodyn. 2017, 44 (2), 95–111.
  4. Bensman, T. J.; Wang, J.; Jayne, J.; Fukushima, L.; Rao, A. P.; D’Argenio, D. Z.; Beringer, P. M. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Cystic Fibrosis. Antimicrob. Agents Chemother. 2017, 61 (10).
  5. Bergen, P. J.; Bulitta, J. B.; Kirkpatrick, C. M. J.; Rogers, K. E.; McGregor, M. J.; Wallis, S. C.; Paterson, D. L.; Nation, R. L.; Lipman, J.; Roberts, J. A. Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. Antimicrob. Agents Chemother. 2017, 61 (5).
  6. Bond, M.; Rabinovich-Guilatt, L.; Selim, S.; Darwish, M.; Tracewell, W.; Robertson, P.; Yang, R.; Malamut, R.; Colucci, P.; Ducharme, M. P.; et al. Effect of Food on the Pharmacokinetics of Single- and Multiple-Dose Hydrocodone Extended Release in Healthy Subjects. Clin. Drug Investig. 2017, 37 (12), 1153–1163.
  7. Bragonzi, A.; Paroni, M.; Pirone, L.; Coladarci, I.; Ascenzioni, F.; Bevivino, A. Environmental Burkholderia Cenocepacia Strain Enhances Fitness by Serial Passages during Long-Term Chronic Airways Infection in Mice. Int. J. Mol. Sci. 2017, 18 (11), 2417.
  8. Bulik, C. C.; Okusanya, Ó. O.; Lakota, E. A.; Forrest, A.; Bhavnani, S. M.; Hoover, J. L.; Andes, D. R.; Ambrose, P. G. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models. Antimicrob. Agents Chemother. 2017, 61 (2).
  9. Bulitta, J. B.; Paik, S. H.; Chi, Y. H.; Kim, T. H.; Shin, S.; Landersdorfer, C. B.; Jiao, Y.; Yadav, R.; Shin, B. S. Characterizing the Time-Course of Antihypertensive Activity and Optimal Dose Range of Fimasartan via Mechanism-Based Population Modeling. Eur. J. Pharm. Sci. 2017, 107, 32–44.
  10. Bulman, Z. P.; Ly, N. S.; Lenhard, J. R.; Holden, P. N.; Bulitta, J. B.; Tsuji, B. T. Influence of RhlR and LasR on Polymyxin Pharmacodynamics in Pseudomonas Aeruginosa: Implications for Quorum Sensing Inhibition with Azithromycin. Antimicrob. Agents Chemother. 2017, 61 (4).
  11. Cai, Y.; Lim, T.-P.; Teo, J. Q.-M.; Sasikala, S.; Chan, E. C. Y.; Hong, Y. J.; Lee, W.; Tan, T. Y.; Tan, T. T.; Koh, T. H. Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia Coli in Time-Kill Studies and in a Hollow-Fiber Infection Model. Antimicrob. Agents Chemother. 2017, 61 (1).
  12. Chen, X.; DuBois, D. C.; Almon, R. R.; Jusko, W. J. Interrelationships between Infliximab and Recombinant Tumor Necrosis Factor-α in Plasma Using Minimal Physiologically Based Pharmacokinetic Models. Drug Metab. Dispos. 2017, 45 (7), 790–797.
  13. Chevance, A.; Jacques, A.; Laurentie, M.; Sanders, P.; Henri, J. The Present and Future of Withdrawal Period Calculations for Milk in the European Union: Focus on Heterogeneous, Nonmonotonic Data. J. Vet. Pharmacol. Ther. 2017, 40 (3), 218–230.
  14. Choquette, A.; Troncy, E.; Guillot, M.; Varin, F.; del Castillo, J. R. E. Pharmacokinetics of Lidocaine Hydrochloride Administered with or without Adrenaline for the Paravertebral Brachial Plexus Block in Dogs. PLoS One 2017, 12 (1).
  15. Collins, J. W.; Hull, J. H.; Dumond, J. B. Comparison of Tenofovir Plasma and Tissue Exposure Using a Population Pharmacokinetic Model and Bootstrap: A Simulation Study from Observed Data. J. Pharmacokinet. Pharmacodyn. 2017, 44 (6), 631–640.
  16. Dave, R. A.; Follman, K. E.; Morris, M. E. γ-Hydroxybutyric Acid (GHB) Pharmacokinetics and Pharmacodynamics: Semi-Mechanistic and Physiologically Relevant PK/PD Model. AAPS J. 2017, 19 (5), 1449–1460.
  17. de Miranda Silva, C.; Rocha, A.; Tozatto, E.; da Silva, L. M.; Donadi, E. A.; Dalla Costa, T.; Lanchote, V. L.; Schmidt, S.; Bulitta, J. B. Development of an Enantioselective and Biomarker-Informed Translational Population Pharmacokinetic/Pharmacodynamic Model for Etodolac. AAPS J. 2017, 19 (6), 1814–1825.
  18. Deshpande, D.; Srivastava, S.; Pasipanodya, J. G.; Lee, P. S.; Gumbo, T. Tedizolid Is Highly Bactericidal in the Treatment of Pulmonary Mycobacterium Avium Complex Disease. J. Antimicrob. Chemother. 2017, 72 (suppl_2), i30–i35.
  19. Deshpande, D.; Srivastava, S.; Pasipanodya, J. G.; Gumbo, T. Linezolid as Treatment for Pulmonary Mycobacterium Avium Disease. J. Antimicrob. Chemother. 2017, 72 (suppl_2), i24–i29.
  20. Dolton, M. J.; D’Argenio, D. Z. Population-Based Meta-Analysis of Roxithromycin Pharmacokinetics: Dosing Implications of Saturable Absorption and Protein Binding. J. Antimicrob. Chemother. 2017, 72 (4), 1129–1136.
  21. Dumond, J. B.; Chen, J.; Cottrell, M.; Trezza, C. R.; Prince, H. M. A.; Sykes, C.; Torrice, C.; White, N.; Malone, S.; Wang, R. Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV‐infected Subjects with Aging Biomarkers. CPT pharmacometrics Syst. Pharmacol. 2017, 6 (2), 128–135.
  22. Dumond, J. B.; Collins, J. W.; Cottrell, M. L.; Trezza, C. R.; Prince, H. M. A.; Sykes, C.; Torrice, C.; White, N.; Malone, S.; Wang, R. P16INK4a, a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV‐infected Subjects. CPT pharmacometrics Syst. Pharmacol. 2017, 6 (2), 120–127.
  23. Finch, N. A.; Zasowski, E. J.; Murray, K. P.; Mynatt, R. P.; Zhao, J. J.; Yost, R.; Pogue, J. M.; Rybak, M. J. A Quasi-Experiment to Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity. Antimicrob. Agents Chemother. 2017, 61 (12).
  24. Gara-Boivin, C.; del Castillo, J. R. E.; Dunn, M. E.; Bédard, C. In Vitro Effects of Dalteparin on Thrombin Generation in Canine Plasma. Vet. Clin. Pathol. 2017, 46 (3), 442–450.
  25. Glassman, P. M.; Balthasar, J. P. Physiologically-Based Modeling to Predict the Clinical Behavior of Monoclonal Antibodies Directed against Lymphocyte Antigens. MAbs 2017, 9 (2), 297–306.
  26. Gray, Z.; Patricelli, P.; DELL’ELCE, A.; ROSSA, C. P.; Ramirez, E.; Formentini, E. Effect of the Bovine Serum and Persister Cells on the Efficacy of Enrofloxacin and Ciprofloxacin against a Strain of Escherichia Coli. Rev. Med. Vet. (Toulouse). 2017, 168 (7–9), 173–182.
  27. Hall, R.; Pasipanodya, J.; Swancutt, M.; Meek, C.; Leff, R.; Gumbo, T. Supervised Machine-Learning Reveals That Old and Obese People Achieve Low Dapsone Concentrations. CPT Pharmacometrics Syst. Pharmacol. 2017, 6 (8), 552–559.
  28. He, H.; Cao, Y. Chemotherapeutic Dosing Implicated by Pharmacodynamic Modeling of in Vitro Cytotoxic Data: A Case Study of Paclitaxel. J. Pharmacokinet. Pharmacodyn. 2017, 44 (5), 491–501.
  29. Jelliffe, R. W. Author’s Reply to Proost:“Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients.” Clin. Pharmacokinet. 2017, 56 (3), 313–316.
  30. Johnson, R. J.; Kerr, C. L.; Enouri, S. S.; Modi, P.; Lascelles, B. D. X.; del Castillo, J. R. E. Pharmacokinetics of Liposomal Encapsulated Buprenorphine Suspension Following Subcutaneous Administration to Cats. J. Vet. Pharmacol. Ther. 2017, 40 (3), 256–269.
  31. Jusko, W. J. Clarification of Contraceptive Drug Pharmacokinetics in Obesity. Contraception 2017, 95 (1), 10–16.
  32. Khot, A.; Tibbitts, J.; Rock, D.; Shah, D. K. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: A Case Study with T-DM1. AAPS J. 2017, 19 (6), 1715–1734.
  33. Kim, T. H.; Shin, S.; Kim, S.; Bulitta, J. B.; Weon, K.-Y.; Joo, S. H.; Ma, E.; Yoo, S. D.; Park, G.-Y.; Kwon, D. R. Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine. Molecules 2017, 22 (9), 1515.
  34. Kim, T. H.; Shin, S.; Shin, J. C.; Bulitta, J. B.; Weon, K.-Y.; Yoo, S. D.; Park, G.-Y.; Jeong, S. W.; Kwon, D. R.; Min, B. S. Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling. Molecules 2017, 22 (9), 1488.
  35. Koch, G.; Jusko, W. J.; Schropp, J. Target-Mediated Drug Disposition with Drug–drug Interaction, Part I: Single Drug Case in Alternative Formulations. J. Pharmacokinet. Pharmacodyn. 2017, 44 (1), 17–26.
  36. Koch, G.; Jusko, W. J.; Schropp, J. Target Mediated Drug Disposition with Drug–drug Interaction, Part II: Competitive and Uncompetitive Cases. J. Pharmacokinet. Pharmacodyn. 2017, 44 (1), 27–42.
  37. Lakota, E. A.; Bader, J. C.; Ong, V.; Bartizal, K.; Miesel, L.; Andes, D. R.; Bhavnani, S. M.; Rubino, C. M.; Ambrose, P. G.; Lepak, A. J. Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters. Antimicrob. Agents Chemother. 2017, 61 (11).
  38. Landersdorfer, C. B.; Findling, R. L.; Frazier, J. A.; Kafantaris, V.; Kirkpatrick, C. M. J. Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics. Clin. Pharmacokinet. 2017, 56 (1), 77–90.
  39. Landersdorfer, C. B.; Nguyen, T.-H.; Lieu, L. T.; Nguyen, G.; Bischof, R. J.; Meeusen, E. N.; Li, J.; Nation, R. L.; McIntosh, M. P. Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model. Antimicrob. Agents Chemother. 2017, 61 (1).
  40. Landersdorfer, C. B.; Wang, J.; Wirth, V.; Chen, K.; Kaye, K. S.; Tsuji, B. T.; Li, J.; Nation, R. L. Pharmacokinetics/Pharmacodynamics of Systemically Administered Polymyxin B against Klebsiella Pneumoniae in Mouse Thigh and Lung Infection Models. J. Antimicrob. Chemother. 2017, 73 (2), 462–468.
  41. Li, M.; Zou, P.; Tyner, K.; Lee, S. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles. AAPS J. 2017, 19 (1), 26–42.
  42. Li, X.; DuBois, D. C.; Almon, R. R.; Jusko, W. J. Effect of Disease-Related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats. Drug Metab. Dispos. 2017, 45 (5), 476–483.
  43. Li, X.; DuBois, D. C.; Almon, R. R.; Jusko, W. J. Modeling Sex Differences in Pharmacokinetics, Pharmacodynamics, and Disease Progression Effects of Naproxen in Rats with Collagen-Induced Arthritis. Drug Metab. Dispos. 2017, 45 (5), 484–491.
  44. Li, X.; DuBois, D. C.; Song, D.; Almon, R. R.; Jusko, W. J.; Chen, X. Modeling Combined Immunosuppressive and Anti-Inflammatory Effects of Dexamethasone and Naproxen in Rats Predicts the Steroid-Sparing Potential of Naproxen. Drug Metab. Dispos. 2017, 45 (7), 834–845.
  45. Liang, Z.; Xu, C.; Dong, L.; Fu, Y.; Wu, Q.; Zhao, J.; Ye, L.; Cai, Z.; Liu, M.; Xia, B. Involvement of UDP-Glucuronosyltransferases in Higenamine Glucuronidation and the Gender and Species Differences in Liver. Biomed. Pharmacother. 2017, 93, 172–179.
  46. Lin, Y.-W.; Zhou, Q. T.; Hu, Y.; Onufrak, N. J.; Sun, S.; Wang, J.; Forrest, A.; Chan, H.-K.; Li, J. Pulmonary Pharmacokinetics of Colistin Following Administration of Dry Powder Aerosols in Rats. Antimicrob. Agents Chemother. 2017, 61 (11).
  47. Lin, Y.-W.; Zhou, Q. T.; Onufrak, N. J.; Wirth, V.; Chen, K.; Wang, J.; Forrest, A.; Chan, H.-K.; Li, J. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic/Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas Aeruginosa in a Mouse Lung Infection Model. Antimicrob. Agents Chemother. 2017, 61 (8).
  48. Liu, D.; Zhang, Y.; Jiang, J.; Choi, J.; Li, X.; Zhu, D.; Xiao, D.; Ding, Y.; Fan, H.; Chen, L. Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn–Research–Confirm Process. Clin. Pharmacokinet. 2017, 56 (8), 925–939.
  49. Martirosov, D. M.; Bidell, M. R.; Pai, M. P.; Scheetz, M. H.; Rosenkranz, S. L.; Lodise, T. P. Relationship between Vancomycin Exposure and Outcomes among Patients with MRSA Bloodstream Infections with Vancomycin Etest® MIC Values of 1.5 Mg/L: A Pilot Study. Diagn. Microbiol. Infect. Dis. 2017, 88 (3), 259–263.
  50. Martirosov, D. M.; Bidell, M. R.; Pai, M. P.; Scheetz, M. H.; Rosenkranz, S. L.; Faragon, C.; Malik, M.; Mendes, R. E.; Jones, R. N.; McNutt, L.-A.; et al. Relationship between Day 1 and Day 2 Vancomycin Area under the Curve Values and Emergence of Heterogeneous Vancomycin-Intermediate Staphylococcus Aureus (HVISA) by Etest® Macromethod among Patients with MRSA Bloodstream Infections: A Pilot Study. BMC Infect. Dis. 2017, 17 (1), 534.
  51. Methaneethorn, J. Population Pharmacokinetic Analyses of Lithium: A Systematic Review. Eur. J. Drug Metab. Pharmacokinet. 2017, 43 (1), 25–34.
  52. Millisor, V. E.; Roberts, J. K.; Sun, Y.; Tang, L.; Daryani, V. M.; Gregornik, D.; Cross, S. J.; Ward, D.; Pauley, J. L.; Molinelli, A. Derivation of New Equations to Estimate Glomerular Filtration Rate in Pediatric Oncology Patients. Pediatr. Nephrol. 2017, 32 (9), 1575–1584.
  53. Mohanan, E.; Panetta, J. C.; Lakshmi, K. M.; Edison, E. S.; Korula, A.; Fouzia, N. A.; Abraham, A.; Viswabandya, A.; Mathews, V.; George, B. Population Pharmacokinetics of Fludarabine in Patients with Aplastic Anemia and Fanconi Anemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Bone Marrow Transplant. 2017, 52 (7), 977.
  54. Morse, B. L.; MacGuire, J. G.; Marino, A. M.; Zhao, Y.; Fox, M.; Zhang, Y.; Shen, H.; Humphreys, W. G.; Marathe, P.; Lai, Y. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. AAPS J. 2017, 19 (6), 1878–1889.
  55. Nanavati, C.; Mager, D. E. Sequential Exposure of Bortezomib and Vorinostat Is Synergistic in Multiple Myeloma Cells. Pharm. Res. 2017, 34 (3), 668–679.
  56. Nanavati, C.; Ruszaj, D.; Mager, D. E. Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts. CPT Pharmacometrics Syst. Pharmacol. 2017, 6 (11), 756–764.
  57. Pai, M. P.; Derstine, B. A.; Lichty, M.; Ross, B. E.; Sullivan, J.; Su, G. L.; Wang, S. C. Relationships of Vancomycin Pharmacokinetics to Body Size and Composition by Computed Tomography Analysis: A Novel “Pharmacomorphomic” Approach. Antimicrob. Agents Chemother. 2017, 61 (11).
  58. Patterson, S. D.; Jones, B. Bioequivalence and Statistics in Clinical Pharmacology; Chapman and Hall/CRC, 2017.
  59. Petraitis, V.; Petraitiene, R.; Hope, W. W.; Walsh, T. J. Endpoint Assessment in Rabbit Models of Invasive Pulmonary Aspergillosis and Mucormycosis. In Vaccines for Invasive Fungal Infections; Springer, 2017; pp 259–277.
  60. Pomeroy, J. J.; Drusano, G. L.; Rodriquez, J. L.; Brown, A. N. Searching for Synergy: Identifying Optimal Antiviral Combination Therapy Using Hepatitis C Virus (HCV) Agents in a Replicon System. Antiviral Res. 2017, 146, 149–152.
  61. Pradhan, S.; Song, B.; Lee, J.; Chae, J.; Im Kim, K.; Back, H.; Han, N.; Kwon, K.; Yun, H. Performance Comparison of First-Order Conditional Estimation with Interaction and Bayesian Estimation Methods for Estimating the Population Parameters and Its Distribution from Data Sets with a Low Number of Subjects. BMC Med. Res. Methodol. 2017, 17 (1), 154.
  62. Proost, J. H. Pharmacokinetic–Pharmacodynamic Modelling of Anesthetic Drugs; Springer, 2017.
  63. Recacha, E.; Machuca, J.; Díaz de Alba, P.; Ramos-Güelfo, M.; Docobo-Pérez, F.; Rodriguez-Beltrán, J.; Blázquez, J.; Pascual, A.; Rodríguez-Martínez, J. M. Quinolone Resistance Reversion by Targeting the SOS Response. MBio 2017, 8 (5).
  64. Rodriguez, C. A.; Agudelo, M.; Zuluaga, A. F.; Vesga, O. In Vivo Pharmacodynamics of Piperacillin/Tazobactam: Implications for Antimicrobial Efficacy and Resistance Suppression with Innovator and Generic Products. Int. J. Antimicrob. Agents 2017, 49 (2), 189–197.
  65. Serrano-Rodríguez, J. M.; Gómez-Díez, M.; Esgueva, M.; Castejón-Riber, C.; Mena-Bravo, A.; Priego-Capote, F.; Ayala, N.; Caballero, J. M. S.; Muñoz, A. Pharmacokinetic/Pharmacodynamic Modeling of Benazepril and Benazeprilat after Administration of Intravenous and Oral Doses of Benazepril in Healthy Horses. Res. Vet. Sci. 2017, 114, 117–122.
  66. Singh, A. P.; Shah, D. K. Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: A Case Study with Trastuzumab Emtansine (T-DM1). AAPS J. 2017, 19 (4), 1054–1070.
  67. Singh, A. P.; Shah, D. K. Measurement and Mathematical Characterization of Cell-Level Pharmacokinetics of Antibody-Drug Conjugates: A Case Study with Trastuzumab-vc-MMAE. Drug Metab. Dispos. 2017, 45 (11), 1120–1132.
  68. Smith, J. A.; Donepudi, R. V; Argoti, P. S.; Giezentanner, A. L.; Jain, R.; Boring, N.; Garcia, E.; Moise, K. J. Exploring the Pharmacokinetic Profile of Remifentanil in Mid-Trimester Gestations Undergoing Fetal Intervention Procedures. Front. Pharmacol. 2017, 8 (11).
  69. Smith, N. M.; Bulman, Z. P.; Sieron, A. O.; Bulitta, J. B.; Holden, P. N.; Nation, R. L.; Li, J.; Wright, G. D.; Tsuji, B. T. Pharmacodynamics of Dose-Escalated ‘Front-Loading’Polymyxin B Regimens against Polymyxin-Resistant Mcr-1-Harbouring Escherichia Coli. J. Antimicrob. Chemother. 2017, 72 (8), 2297–2303.
  70. Song, G.; Pacini, G.; Ahrén, B.; D’Argenio, D. Z. Glucagon Increases Insulin Levels by Stimulating Insulin Secretion without Effect on Insulin Clearance in Mice. Peptides 2017, 88, 74–79.
  71. Srivastava, S.; Deshpande, D.; Gumbo, T. Failure of the Azithromycin and Ethambutol Combination Regimen in the Hollow-Fibre System Model of Pulmonary Mycobacterium Avium Infection Is Due to Acquired Resistance. J. Antimicrob. Chemother. 2017, 72, i20–i23.
  72. Srivastava, S.; Magombedze, G.; Koeuth, T.; Sherman, C.; Pasipanodya, J. G.; Raj, P.; Wakeland, E.; Deshpande, D.; Gumbo, T. Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis. Antimicrob. Agents Chemother. 2017, 61 (8).
  73. Stauffer, M. E.; Hutson, P.; Kaufman, A. S.; Morrison, A. The Adherence Rate Threshold Is Drug Specific. Drugs R. D. 2017, 17 (4), 645–653.
  74. Taich, P.; Del Sole, M.; Buontempo, F.; Williams, G.; Winter, U.; Sgroi, M.; Chantada, G.; Schaiquevich, P. Ocular Topotecan Pharmacokinetics Following Topical Administration to Rabbits for Diffused Anterior Retinoblastoma. J. Pharm. Pharmacol. 2017, 69 (5), 574–581.
  75. Thakur, A. K. Some Statistical Principles in Compartmental Analysis. In Compartmental Distribution Of Radiotracers; CRC Press, 2017; pp 155–188.
  76. Thamlikitkul, V.; Dubrovskaya, Y.; Manchandani, P.; Ngamprasertchai, T.; Boonyasiri, A.; Babic, J. T.; Tam, V. H. Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency. Antimicrob. Agents Chemother. 2017, 61 (1).
  77. Weiss, M. Empirical Models for Fitting of Oral Concentration Time Curves with and without an Intravenous Reference. J. Pharmacokinet. Pharmacodyn. 2017, 44 (3), 193–201.
  78. Weiss, M.; Krejcie, T. C.; Avram, M. J. Beta Blockade Increases Pulmonary and Systemic Transit Time Heterogeneity: Evaluation Based on Indocyanine Green Kinetics in Healthy Volunteers. Clin. Physiol. Funct. Imaging 2017, 37 (3), 270–275.
  79. Wittau, M.; Paschke, S.; Kurlbaum, M.; Scheele, J.; Ly, N. S.; Hemper, E.; Kornmann, M.; Henne-Bruns, D.; Bulitta, J. B. Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery. Antimicrob. Agents Chemother. 2017, 61 (1).
  80. Wu, A. M.; Shively, J. E.; Raubitschek, A. A.; Sherman, M. A.; Olafsen, T. Covalent Disulfide-Linked Diabodies and Uses Thereof, September 19, 2017.
  81. Yadav, R.; Bulitta, J. B.; Nation, R. L.; Landersdorfer, C. B. Optimization of Synergistic Combination Regimens against Carbapenem-and Aminoglycoside-Resistant Clinical Pseudomonas Aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling. Antimicrob. Agents Chemother. 2017, 61 (1).
  82. Yadav, R.; Bulitta, J. B.; Schneider, E. K.; Shin, B. S.; Velkov, T.; Nation, R. L.; Landersdorfer, C. B. Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas Aeruginosa Determined via Mechanistic Studies and Modeling. Antimicrob. Agents Chemother. 2017, 61 (12).
  83. Yadav, R.; Bulitta, J. B.; Wang, J.; Nation, R. L.; Landersdorfer, C. B. Evaluation of PK/PD Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas Aeruginosa in a Murine Thigh Infection Model Using Humanized Dosing Schemes. Antimicrob. Agents Chemother. 2017, 61 (12).
  84. Zhang, C.; Wang, C.; Li, W.; Wu, R.; Guo, Y.; Cheng, D.; Yang, Y.; Androulakis, I. P.; Kong, A.-N. Pharmacokinetics and Pharmacodynamics of the Triterpenoid Ursolic Acid in Regulating the Antioxidant, Anti-Inflammatory, and Epigenetic Gene Responses in Rat Leukocytes. Mol. Pharm. 2017, 14 (11), 3709–3717.
  85. Zhang, Y.; Hu, K.; Beumer, J. H.; Bakkenist, C. J.; D’Argenio, D. Z. RAD-ADAPT: Software for Modelling Clonogenic Assay Data in Radiation Biology. DNA Repair (Amst). 2017, 52, 24–30. https://doi.org/10.1016/j.dnarep.2017.02.004.
  86. Zhou, J.; Ledesma, K. R.; Chang, K.-T.; Abodakpi, H.; Gao, S.; Tam, V. H. Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter Baumannii in a Neutropenic Murine Pneumonia Model. Antimicrob. Agents Chemother. 2017, 61 (5).
  87. Zhou, J.; Ren, Y.; Liu, D.; Hu, B.; Kambhampati, S. R. P.; Chigutsa, E.; Sykes, A. K.; Turner, P. K. A Model-Based Meta-Analysis Study on the Quantitative Relationship of Pharmacokinetics: Fasting Plasma Glucose Corrected Urinary Glucose Excretion—HbA1c for Sodium Glucose Co-Transporter-2 Inhibitors in T2DM Patients. In Journal of Pharmacokinetics and Pharmacodynamics; Springer, 2017; Vol. 44, pp S11–S11.